Vivani Medical, Inc. VANI
1.09 USD +0.04 (+3.81%)
As ofNov 19, 2026, 12:19 PM EST
1.06 Day range 1.13
0.80 52-week range 1.66
- YTD
- -11.38%
- 1 year
- -20.44%
News
globenewswire.com Vivani Medical Announces Private Placement Equity Financing ALAMEDA, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting…
benzinga.com Vivani Medical Advances Long-Acting Semaglutide Implant Toward Phase 2 Trial in 2027 Vivani Medical Inc. (NASDAQ:VANI) stock soared on Thursday after reporting positive topline results from its Phase 1 SLIM-1 clinical trial, showing that its experimental semaglutide implant matched…
benzinga.com Vivani Medical Advances Long-Acting Semaglutide Implant Toward Phase 2 Trial in 2027 Vivani Medical reports Phase 1 results for its NPM-139 implant, matching Wegovy weight loss without treatment-related side effects.
globenewswire.com Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects Strong NPM-139 safety and tolerability profile: -0 of 10 NPM-139 subjects experienced adverse events reported as treatment related -5 of 10 Wegovy subjects (control group) experienced adverse events…benzinga.com Vivani Medical Q3 EPS $(0.08), Inline Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 27.27 percent increase over losses of $(0.11) per share from the same…
